Extracellular histamine inhibits antigen-induced histamine release from human basophils in vitro, apparently via H2-receptors since it is antagonized by metiamide and burimamide (Lichtenstein & Gillespie, 1975) . If there are H2-receptors on human pulmonary mast cells which modulate histamine release via a similar mechanism, then H2-receptor antagonists may potentiate antigen-induced release of histamine and leukotrienes with potential adverse effects in asthmatic patients receiving these drugs for unrelated disorders such as peptic ulcers (Henry, 1984) . However, in experiments with human lung fragments in vitro (Platshon & Kaliner, 1978) , single concentrations (50 ,uM) of cimetidine or metiamide did not significantly alter the immunological release of histamine and slowreacting substance of anaphylaxis, which is now known to comprise leukotrienes (Samuelsson, 1980) .
Ranitidine is a new H2-receptor antagonist which is five times more potent than cimetidine (Daly et al., 1981) . It may be preferable for the treatment of peptic ulcers because it does not have the inhibitory effects on hepatic drug metabolism which occur with cimetidine (see Henry, 1984) . The present experiments were performed to determine the effects of ranitidine, over a wide concentration range, on the release of histamine and leukotrienes from human lung fragments.
Macroscopically normal human lung tissue was obtained from operative specimens removed from patients undergoing resections for lung cancer. Lung fragments which were sensitized and challenged with Dermatophagoides pteronyssinus extract as described previously (Hughes et al., 1983) were pre-incubated with ranitidine (0.01-100 ,umolIl) at 37°C for 15 min before antigen challenge. The release of histamine and leukotrienes was determined by spectrofluorimetric assay and bioassay respectively as described (Hughes et al., 1983) .
Following antigen challenge the release of histamine was 30.5 5.1% (mean s.e. mean, n = 6 lung specimens) of original tissue histamine content and the release of leukotrienes was equivalent to 2.25 0.87 nmole/ml leukotriene E4 (mean + s.e. mean, n = 4). Ranitidine, over a wide concentration range, had little effect on antigen-induced mediator release (Table 1) . Platshon & Kaliner (1978) , suggesting that human pulmonary mast cells do not possess functional histamine H2-receptors. Thus it is evident that there are fundamental differences between these mast cells and human basophils in which it appears that histamine H2-receptors are responsible for feedback inhibition of histamine release (Lichtenstein & Gillespie, 1975) .
In general, the effects of ranitidine on leukotriene release resembled its effects on histamine release. Although one concentration (1 ,umol/l) of ranitidine significantly reduced leukotriene release, the biological interpretation of this finding remains uncertain because the effect was small and not apparently concentrationdependent (Table 1) . It has been suggested that lipoxygenase products of arachidonic acid have a facilitatory role in histamine release (Peters et al., 1981) There are at least two reasons why the results of this study should be interpreted with caution. Firstly, the sampling time over 8 h after an oral dose yields only 6-7 h period for the determination of the terminal half-life. With a mean halflife of 7 to 8 h, as reported in that study, this is clearly too short for an accurate estimate of the apparent elimination rate constant. Secondly, the design of the intravenous study was such that the results are biased towards the clearance values obtained during the oral study. Differences between oral and intravenous clearances of more than 30% may have been missed. In the intravenous study, a loading dose was chosen to achieve a serum concentration that would be expected at steady-state with the clearance value found in the oral study. The observation time on a constant infusion rate was only about 1 h (disregarding the early distribution of about 30 min). This is too short for confirmation of steady-state even if multiple samples are obtained. Assuming a half-life of 8 h, the change in the serum concentration within 1 h is only about 10% of the difference between the current concentration and the steady-state value. In case of a difference between oral and intravenous clearances of, say, 30% the expected systematic shift in serum concentration during the observa-
